The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily
Open Access
- 1 May 2005
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 6 (3) , 151-154
- https://doi.org/10.1111/j.1468-1293.2005.00279.x
Abstract
Tenofovir (TDF) co-administered with didanosine (ddI) 400 mg increases ddI plasma concentrations by up to 60%, raising concerns over toxicity. To limit this interaction, the dosage of ddI may be reduced to 250 mg once daily when co-prescribed with TDF. In this clinical cohort, highly active antiretroviral therapy regimens containing TDF and ddI 250 mg were significantly better tolerated than combinations with TDF and ddI at a dose of 400 mg. Low-dose ddI 250 mg once daily plus TDF as part of antiretroviral therapy was effective.Keywords
This publication has 5 references indexed in Scilit:
- Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adultsThe Lancet, 2004
- Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral loadAIDS, 2004
- Fatal Lactic Acidosis and Acute Renal Failure after Addition of Tenofovir to an Antiretroviral Regimen Containing DidanosineClinical Infectious Diseases, 2003
- The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patientsAIDS, 2002
- Effect of Food on the Oral Bioavailability of Didanosine from Encapsulated Enteric-Coated BeadsThe Journal of Clinical Pharmacology, 2002